PI3K inhibitors are mainly used in colorectal cancer patients with PIK3CA mutations, in combination with chemotherapy or other drugs, to improve efficacy and overcome resistance (Temraz et al., 2015; García-García et al., 2015). The gene discussed is PIK3CA; the disease is colorectal cancer.